Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.63 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.62 |
| ▸ | RARB | P10826 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3001656 | 1.00 | TP53 (0.65) | TP53TSHRPLA2G4BNR5A1RARB | |
| SCHEMBL3001402 | 1.00 | TP53 (0.65) | TP53TSHRPLA2G4BNR5A1RARB | |
| SCHEMBL5033563 | 0.98 | TP53 (0.62) | TP53TSHRPLA2G4BNR5A1RARB | |
| SCHEMBL12243086 | 0.95 | RARB (0.68) | TP53TSHRPLA2G4BNR5A1RARB | |
| SCHEMBL12243087 | 0.95 | RARB (0.68) | TP53TSHRPLA2G4BNR5A1RARB | |
| SCHEMBL5033226 | 0.94 | GAA (0.56) | TP53TSHRPLA2G4BNR5A1RARB | |
| SCHEMBL12243089 | 0.93 | RARB (0.65) | TP53TSHRPLA2G4BNR5A1RARB | |
| SCHEMBL17253328 | 0.93 | RARB (0.65) | TP53TSHRPLA2G4BNR5A1RARB | |
| SCHEMBL12243091 | 0.87 | RARB (0.55) | TP53TSHRPLA2G4BNR5A1RARB | |
| SCHEMBL9781935 | 0.87 | L3MBTL1 (0.56) | TP53TSHRPLA2G4BGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858875-A2 | ANETHOLE DITHIOLETHIONE AND OTHER DITHIOLETHIONES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DYSFUNCTION OF MONOAMINE NEUROTRANSMISSION | Solvay Pharmaceuticals B.V. (NL) | 2007-11-28 | — | — | EP | disclosed |
| US-20060194971-A1 | Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neruotransmission | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-08-31 | — | — | US | disclosed |
| WO-2006089861-A2 | ANETHOLE DITHIOLETHIONE AND OTHER DITHIOLETHIONES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DYSFUNCTION OF MONOAMINE NEUROTRANSMISSION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194971-A1 | Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neruotransmission | MAOB, MAOA, DAO | TP53 4480/4885TSHR 1381/4885PLA2G4B 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.